At the news
? MIXEDIMPACT 6/10 8-K filed Mar 19, 2026 at 06:00 ET
Marker Therapeutics reported its 2025 financial results and provided clinical updates, highlighting a 66% objective response rate in relapsed non-Hodgkin lymphoma from its APOLLO study and promising pancreatic cancer research published in Nature Medicine. The company ended 2025 with $17 million in cash, sufficient to fund operations through Q4 2026, while R&D expenses decreased to $11.8 million. The stock has a market cap of $22 million.
- 66% objective response rate (8/12 patients) in relapsed non-Hodgkin lymphoma with MT-601 therapy, including 50% complete responses
- 78% objective response rate (7/9 patients) in Hodgkin lymphoma
- Nature Medicine publication showed up to 84.6% disease control rate in pancreatic cancer when combined with chemotherapy
- Cash position of $17 million at year-end 2025, expected to fund operations through Q4 2026
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access